Figure 5From: A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell diseaseEffect of prasugrel vs. placebo on biomarkers of disease-related platelet activation. A. Percent of platelets positive for platelet surface P-selectin, B. Plasma soluble P-selectin, C. Serum TXB2, D. plasma soluble CD40L. Prasugrel = black bars; placebo = grey bars. Results are mean ± SDBack to article page